Skip to main content
main-content

05.08.2019 | Research Article | Ausgabe 5/2020

Clinical and Translational Oncology 5/2020

Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

Zeitschrift:
Clinical and Translational Oncology > Ausgabe 5/2020
Autoren:
A. Viúdez, A. Carmona-Bayonas, J. Gallego, A. Lacalle, R. Hernández, J. M. Cano, I. Macías, A. Custodio, E. Martínez de Castro, A. Sánchez, L. Iglesia, P. Reguera, L. Visa, A. Azkarate, M. Sánchez-Cánovas, M. Mangas, M. L. Limón, A. Martínez-Torrón, E. Asensio, A. Ramchandani, A. Martín-Carnicero, A. Hurtado, P. Cerdà, M. Garrido, R. Sánchez-Bayonas, R. Serrano, P. Jiménez-Fonseca, the AGAMENON Study Group
Wichtige Hinweise
Members of “the AGAMENON Study Group” are listed in acknowledgement section.
A. Viúdez and A. Carmona-Bayonas equally contributed to this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Background

The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression.

Method

The sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response. The objective was to explore the optimal duration of first-line chemotherapy. A frailty multi-state model was conducted.

Results

415 patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, n = 123), complete treatment withdrawal prior to progression (52%, n = 216), and full treatment until progression (18%, n = 76). The hazard of tumor progression decreased by 19% per month with the full treatment regimen. However, we found no evidence that fluoropyrimidine maintenance (hazard ratio [HR] 1.07, confidence interval [CI] 95%, 0.69–1.65) worsened progression-free survival (PFS) with respect to treatment until progression. Predictive factors for PFS were ECOG performance status, ≥ 3 metastatic sites, prior tumor response, and bone metastases. Toxicity grade 3/4 was more common in those who continued the full treatment until progression vs fluoropyrimidine maintenance (16% vs 6%).

Conclusion

The longer duration of the full initial regimen exerted a protective effect on the patients of this registry. Platinum discontinuation followed by fluoropyrimidine maintenance yields comparable efficacy to treatment up to PD, with a lower rate of serious adverse events.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2020

Clinical and Translational Oncology 5/2020 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise